李磊;刘建勋;任建勋;郭浩;林成仁;
LI Lei;LIU Jian-xun;REN Jian-xun;GUO Hao;LIN Cheng-ren;Institute of Basic Medical Sciences of Xiyuan Hospital,China Academy of Chinese Medical Sciences;Beijing Key Laboratory of Chinese Materia Pharmacology;

• 1:中国中医科学院西苑医院基础医学研究所
• 2:中药药理北京市重点实验室

摘要(Abstract)：

冠状动脉微循环功能障碍(CMD)是心脏X综合征、经皮冠状动脉介入治疗(PCI)后无复流等微循环病变的共同发病机制。随着现代影像学的迅速发展,CMD的发生和防治得到越来越多的关注。CMD动物模型是研究疾病发病机制及评价药物作用的必不可少的工具,选择合适的CMD动物模型建立方法是开展CMD实验研究首先面临的问题。临床及实验研究显示,中医药在CMD的防治方面具有一定的特色。如何进一步阐明中药作用机制寻求最佳的中西医结合治疗方案,将是中医药干预CMD的研究重点。该文将从冠状动脉微循环障碍动物模型的建立评价方法及中医药防治冠状动脉微血管环障碍的研究进展进行综述,旨为冠状动脉微循环障碍实验及中医药的实验研究提供参考。
Coronary microvascular dysfunction(CMD) is a common mechanism for some heart disease like cardiac X syndrome and no-reflow phenomenon after percutaneous coronary intervention( PCI). With the development of medical imageology,CMD has received increased attention. Animal model of CMD is indispensable tool for the research of pathogenesis and treatment evaluation,therefor choose an appropriate animal model is the first issue to carry out CMD research. Experimental and clinical studies have shown unique effectiveness of traditional Chinese medicine( TCM) in CMD therapy. Clarifying of the TCM therapeutic effect mechanisms and seeking an optimal solution of combination of traditional Chinese and western medicine will be the focus of future research. This paper reviewed the establishment and evaluation of CMD animal model,as well as the intervention study of TCM on CMD. The article aims to provide reference for the basic research of CMD and the TCM experimental study on CMD.

关键词(KeyWords)： 冠状动脉微循环功能障碍;心脏X综合征;微血管性心绞痛;PCI术后无复流;中医药;动物模型
coronary microvascular dysfunction;cardiac X-syndrome;microvascular angina;no-reflow after PCI;traditional Chinese medicine;animal model

Abstract:

Keywords:

基金项目(Foundation): 国家重点基础研究发展计划(973)项目(2015CB554405)

作者(Authors): 李磊;刘建勋;任建勋;郭浩;林成仁;
LI Lei;LIU Jian-xun;REN Jian-xun;GUO Hao;LIN Cheng-ren;Institute of Basic Medical Sciences of Xiyuan Hospital,China Academy of Chinese Medical Sciences;Beijing Key Laboratory of Chinese Materia Pharmacology;

DOI: 10.19540/j.cnki.cjcmm.20161222.041

参考文献(References)：

• [1]Van Oosterhout M F,Willigers H M,Reneman R S,et al.Fluorescent microspheres to measure organ perfusion:validation of a simplified sample processing technique[J].Am J Physiol,1995,269(2 Pt 2):H725.
• [2]Titterington J S,Hung O Y,Wenger N K.Microvascular angina:an update on diagnosis and treatment[J].Future Cardiol,2015,11(2):229.
• [3]Fordyce C B,Gersh B J,Stone G W,et al.Novel therapeutics in myocardial infarction:targeting microvascular dysfunction and reperfusion injury[J].Trends Pharmacol Sci,2015,36(9):605.
• [4]Pries A R,Reglin B.Coronary microcirculatory pathophysiology:can we afford it to remain a black box[J].Eur Heart J,2016,doi:10.1093/eurheartj/ehv760.
• [5]Camici Paolo G,Crea Filippo.Coronary microvascular dysfunction[J].New Engl J Med,2007,356(8):830.
• [6]Crea F,Camici P G,Bairey Merz C N.Coronary microvascular dysfunction:an update[J].Eur Heart J,2014,35(17):1101.
• [7]Schwartz R S,Burke A,Farb A,et al.Microemboli and microvascular obstruction in acute coronary thrombosis and sudden coronary death:relation to epicardial plaque histopathology[J].J Am Coll Cardiol,2009,54(23):2167.
• [8]Do L,Wilson M W,Krug R,et al.MRI monitoring of function,perfusion and viability in microembolized moderately ischemic myocardium[J].Int J Cardiovasc Imaging,2015,31(6):1179.
• [9]Wang J,Chen H,Su Q,et al.The PTEN/Akt signaling pathway mediates myocardial apoptosis in swine after coronary microembolization[J].J Cardiovasc Pharmacol Ther,2016,21(5):471.
• [10]Zhang Z,Takarada S,Molloi S.Assessment of coronary microcirculation in a swine animal model[J].Am J Physiol Heart Circ Physiol,2011,301(2):H402.
• [11]Dorge H,Schulz R,Belosjorow S,et al.Coronary microembolization:the role of TNF-alpha in contractile dysfunction[J].J Mol Cell Cardiol,2002,34(1):51.
• [12]Saeed M,Bajwa H Z,Do L,et al.Multi-detector CT and MRI of microembolized myocardial infarct:monitoring of left ventricular function,perfusion,and myocardial viability in a swine model[J].Acta Radiol,2016,57(2):215.
• [13]Heusch G,Kleinbongard P,Bose D,et al.Coronary microembolization:from bedside to bench and back to bedside[J].Circulation,2009,120(18):1822.
• [14]Wang H,Zhong W J,Huang M W,et al.Efficacy of dual antiplatelet therapy combined with Naoxintong capsules[see text]following coronary microembolization induced by homologous microthrombi in rats[J].Chin J Integr Med,2011,17(12):917.
• [15]Li Shumei,Zhong Shishun,Zeng Kai,et al.Blockade of NF-κBby pyrrolidine dithiocarbamate attenuates myocardial inflammatory response and ventricular dysfunction following coronary microembolization induced by homologous microthrombi in rats[J].Basic Res Cardiol,2009,105(1):139.
• [16]王贤良,苏立硕,毛静远,等.理气化痰活血方药对大鼠冠脉微血管血栓形成及阻塞的影响[J].中国医学科学院学报,2016,38(3):260.
• [17]Zhang Y,Ma X J,Guo C Y,et al.Pretreatment with a combination of ligustrazine and berberine improves cardiac function in rats with coronary microembolization[J].Acta Pharmacol Sin,2016,37(4):463.
• [18]Kanazawa H,Tseliou E,Malliaras K,et al.Cellular postconditioning:allogeneic cardiosphere-derived cells reduce infarct size and attenuate microvascular obstruction when administered after reperfusion in pigs with acute myocardial infarction[J].Circ Heart Fail,2015,8(2):322.
• [19]Hernandez-Resendiz S,Palma-Flores C,De Los Santos S,et al.Reduction of no-reflow and reperfusion injury with the synthetic17 beta-aminoestrogen compound Prolame is associated with PI3 K/Akt/e NOS signaling cascade[J].Basic Res Cardiol,2015,110(2):1.
• [20]Uitterdijk A,Sneep S,Van Duin R W,et al.Serial measurement of h FABP and high-sensitivity troponin I post-PCI in STEMI:how fast and accurate can myocardial infarct size and no-reflow be predicted[J].Am J Physiol Heart Circ Physiol,2013,305(7):H1104.
• [21]Paradies Valeria,Masi Filippo,Bartolomucci Francesco,et al.No reflow-phenomenon:from current state of the Art to future perspectives[J].AIMS Med Sci,2015,2(4):374.
• [22]Charron T,Jaffe R,Segev A,et al.Effects of distal embolization on the timing of platelet and inflammatory cell activation in interventional coronary no-reflow[J].Thromb Res,2010,126(1):50.
• [23]Skyschally A,Walter B,Heusch G.Coronary microembolization during early reperfusion:infarct extension,but protection by ischaemic postconditioning[J].Eur Heart J,2013,34(42):3314.
• [24]Krueger M A,Huke S S,Glenny R W.Visualizing regional myocardial blood flow in the mouse[J].Circ Res,2013,112(9):e88.
• [25]Han B,Zhang X,Zhang Q,et al.Protective effects of salvianolate on microvascular flow in a porcine model of myocardial ischaemia and reperfusion[J].Arch Cardiovasc Dis,2011,104(5):313.
• [26]Bartoli C R,Okabe K,Akiyama I,et al.Repeat microsphere delivery for serial measurement of regional blood perfusion in the chronically instrumented,conscious canine[J].J Surg Res,2008,145(1):135.
• [27]Leong X F,Mustafa M R,Das S,et al.Association of elevated blood pressure and impaired vasorelaxation in experimental Sprague-Dawley rats fed with heated vegetable oil[J].Lipids Health Dis,2010,9:66.
• [28]Yetgin T,Uitterdijk A,Te Lintel Hekkert M,et al.Limitation of infarct size and no-reflow by intracoronary adenosine depends critically on dose and duration[J].JACC Cardiovasc Interv,2015,8(15):1990.
• [29]Shao L,Zhang Y,Ma A,et al.Atorvastatin preconditioning improves the forward blood flow in the no-reflow rats[J].Fundam Clin Pharmacol,2014,28(1):42.
• [30]Jin H,Yun H,Ma J,et al.Coronary microembolization with normal epicardial coronary arteries and no visible infarcts on nitrobluetetrazolium chloride-stained specimens:evaluation with cardiac magnetic resonance imaging in a swine model[J].Korean J Radiol,2016,17(1):83.
• [31]卢健棋,温志浩.中医药干预冠脉微循环障碍的研究近况[J].中国中医基础医学杂志,2013(5):597.
• [32]毛静远,王恒和,葛永彬,等.51例心脏X综合征患者证候特点分析[J].中医杂志,2007(12):1111.
• [33]王贤良,苏立硕,毛静远,等.理气化痰活血方药对大鼠冠脉微血管血栓形成及阻塞的影响[J].中国医学科学院学报,2016(3):260.
• [34]李蓓,毛莉,陈荣鸾.麝香保心丸对心脏X综合征患者的疗效观察[J].中西医结合心脑血管病杂志,2009,7(1):88.
• [35]周利平,蒋少华,熊婧.通心络胶囊治疗心脏X综合征的疗效观察[J].中西医结合心脑血管病杂志,2012,10(7):868.
• [36]刘寨华,张华敏,唐丹丽,等.从“阳虚痰瘀”探讨中医对心肌缺血再灌注无复流的认识[J].中国中医基础医学杂志,2014(2):166.
• [37]翟昂帅,张军平,郭晓辰,等.伏邪理论与治未病思想在防治PCI术后无复流的应用探讨[J].中华中医药学刊,2012(11):2430.
• [38]周欢,张军平.从“大气怫郁”角度探讨冠心病介入术后无复流机制[J].中华中医药杂志,2016(7):2621.
• [39]刘积伦,何亚军,武胜,等.通心络胶囊对急性心肌梗死患者急诊支架置入术中无复流的临床观察[J].疑难病杂志,2014(1):80.
• [40]Jaffe R,Charron T,Puley G,et al.Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention[J].Circulation,2008,117(24):3152.
• [41]Saitoh Shu-Ichi,Onogi Futoshi,Aikawa Kazuhiko,et al.Multiple endothelial injury in epicardial coronary artery induces downstream microvascular spasm as well as remodeling partly via thromboxane A2[J].J Am Coll Cardiol,2001,37(1):308.
• [42]He F,Xu B L,Chen C,et al.Methylophiopogonanone A suppresses ischemia/reperfusion-induced myocardial apoptosis in mice via activating PI3 K/Akt/e NOS signaling pathway[J].Acta Pharmacol Sin,2016,37(6):763.
• [43]Shibutani S,Osanai T,Ashitate T,et al.Coronary vasospasm induced in transgenic mouse with increased phospholipase C-delta1activity[J].Circulation,2012,125(8):1027.
• [44]史大卓,高铸烨,段文慧.急性心肌梗死血运重建后心肌组织无复流和靶向治疗的思考[J].中医杂志,2014(10):832.
• [45]刘建勋,任钧国.源于中医临床的中药复方功效的现代研究思路与方法[J].世界科学技术---中医药现代化,2015(7):1372.